Innate Pharma
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
6
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 25 to 30, 2026 · next Dec 25
- 1 fee due Jan 9, 2027The maintenance fee for Treatment of Peripheral T Cell Lymphoma (US 10,344,087) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Treatment of Head and Neck Cancer (US 11,795,222) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 2 fees due Jun 19 to 30, 2027 · next Jun 19
- 1 fee due Jul 2, 2027The maintenance fee for KIR3DL2 Binding Agents (US 11,858,990) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Variable regions for NKp46 binding proteins (US 11,891,444) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for KIR3DL2 Binding Agents (US 10,577,419) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 2 fees due Oct 16 to 30, 2027 · next Oct 16
Recent changes
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,732,131 | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,160,810 | Monoclonal antibodies against NKG2A In force · From the USPTO record | In force | From the USPTO record | |
| US 7,803,376 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using NK Cell Potentiating Compounds In force · High confidence | In force | High confidence | |
| US 8,993,319 | Monoclonal antibodies against NKG2A In force · From the USPTO record | In force | From the USPTO record | |
| US 8,388,970 | Kir-Binding Agents and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,447,185 | Compositions and Methods for Treating Proliferative Disorders In force · High confidence | In force | High confidence | |
| US 9,067,997 | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,675,359 | Enzymatic conjugation of antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,688,180 | Combination of Anti-Kir and ANTI-CTLA-4 Antibodies to Treat Cancer In force · High confidence | In force | High confidence | |
| US 10,344,087 | Treatment of Peripheral T Cell Lymphoma In force · High confidence | In force | High confidence |
Also on record, not counted in the 52: 11 patents in force now held by others · 25 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
18 pending · 14 abandoned · 49 no status recorded